Media Room



Latest News Releases
Apr 2, 2019

Nektar Therapeutics (Nasdaq: NKTR) today presented preclinical data on its immuno-oncology pipeline candidates, bempegaldesleukin (NKTR-214 or bempeg), a CD122-preferential IL-2 pathway agonist,...

Apr 1, 2019

Vaccibody AS and Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of new preclinical data for VB10.NEO, a personalized neoantigen cancer vaccine, combined with bempegaldesleukin...

Mar 6, 2019

Nektar Therapeutics (Nasdaq: NKTR) today announced that its Chief Scientific Officer, Jonathan Zalevsky, Ph.D., is scheduled to present at the Cowen and Company 39th Annual Health Care Conference...

More »

Multimedia Libraries
Media Contacts
Dan Budwick
Pure Communications, Inc.

More »

Follow Us on LinkedIn
Follow Us on Twitter

Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide